surmount trial tirzepatide surmount-1 weight loss results Reduction of prevalence of patients meeting the criteria for Tirzepatide for maintenance of bodyweight

These results support the potential of this molecule for people living with type 2 diabetes. Retatrutide also showed clinically meaningful improvements from baseline across key cardiovascular risk factors, including non-HDL cholesterol, triglycerides and systolic blood pressure

From start to finish, Klinic provides continuous support and an all-online service, making it easier than ever to take the next step in managing your health

Le Roith D, Werner H, Beitner-Johnson D, Roberts CT Jr

From a pharmacological perspective, these medications can generally be stopped abruptly without causing acute adverse effects or rebound phenomena